Regulatory Events (Spanish only)
The regulatory events included in this section correspond exactly with those sent to the Spanish Stock Exchange Commission (CNMV) and published by them on their web site.
Date |
PDF
| Regulatory Event |
Content |
28/07/2010 |
 |
Almirall announces that Sativex® receives regulatory authorisation in Spain |
|
26/07/2010 |
|
Almirall signs a co-promotion agreement with Pfizer to commercialise Conbriza® in Spain, a new therapeutic option to treat osteoporosis |
|
23/07/2010 |
|
Almirall announces an agreement with Meda |
|
15/06/2010 |
|
Almirall announces an international agreement with Basilea to commercialize Toctino® (alitretinoin) for severe chronic hand eczema |
|
01/06/2010 |
|
Almirall updates 2010 financial guidance |
|
20/05/2010 |
|
Almirall announces that regulators in UK and Spain confirm Sativex® is approvable |
|
14/05/2010 |
|
Announcement of dividend approval and other agreements reached at today's AGM |
|
11/05/2010 |
|
Almirall to present data from studies of Eklira® (aclidinium bromide) in Chronic Obstructive Pulmonary Disease (COPD) and LAS100977 in asthma |
|
10/05/2010 |
|
Information related to the Long term incentive plan for Executives |
|
05/03/2010 |
|
Announcement of next AGM on May 14th 2010 in Barcelona |
|
25/02/2010 |
|
Announcement of the approvals taken by the Board of Directors related to the Art. 116 of the Spanish Exchange Law report, the report on the Remuneration Policy adn the Audit Commitee Report 2009 |
|
08/02/2010 |
|
Almirall announced silodosin has been approved by the European Commission |
|
26/01/2010 |
|
Almirall announces that it has strengthened its focus to the twice-daily dosing of Eklira® in Chronic Obstructive Pulmonary Disease (COPD) |
|
07/01/2010 |
|
Announcement of positive results from the ACCORD COPD I Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) |
Date |
PDF
| Regulatory Event |
Content |
17/12/2009 |
|
Announcement of an agreement between Almirall and Forest Laboratories to expand respiratory collaboration |
|
10/11/2009 |
|
Announcement of a US$ 15 M equity investment in Ironwood Pharmaceuticals for linaclotide |
|
20/10/2009 |
|
Announcement of Eklira update: Positive results in a comparative trial and announcement of new Phase III studies |
|
09/09/2009 |
|
Announcement of the filing of once daily aclidinium bromide for COPD in Europe in early 2010 |
|
30/07/2009 |
|
1st Half 2009 Financial results presentation |
|
30/07/2009 |
|
1st Half 2009 Financial Results Presentation to analysts and investors |
|
01/07/2009 |
|
Announcement of the change to our company name from Laboratorios Almirall, S.A. to Almirall, S.A. |
|
22/05/2009 |
|
Announcement of dividend approval and other agreements reached at today's AGM. |
|
04/05/2009 |
|
Announcement of a pan-European licensing-in agreement with Ironwood for linaclotide, a novel gastrointestinal compound |
|
30/04/2009 |
|
Announcement of an update of the respiratory pipeline |
|
03/04/2009 |
|
Announcement of a co-marketing agreement with Recordati for the marketing of silodosin in Spain, a new compound for benign prostatic hyperplasia |
|
01/04/2009 |
|
Announcement of a milestone payment of £8 million (approx. € 8,6 million), after the positive results in the Sativex's phase III study, to its partner GW Pharmaceuticals plc. and for which Almirall has the marketing rights throught Europe, expect in the United Kingdom |
|
12/03/2009 |
|
Announcement of positive preliminary phase III results of Sativex for the treatment of spasticity, for which Almirall has the marketing rights throught Europe, expect in the United Kingdom |
|
06/03/2009 |
|
Announcement of an update on the Aclidinium Bromide Clinical Development Program |
|
27/02/2009 |
|
Announcement of next AGM on May 22nd 2009 in Barcelona |
|
27/02/2009 |
|
2nd Half 2008 Financial results information |
|
27/02/2009 |
|
2008 Corporate Governance Annual Report |
|
13/01/2009 |
|
Announcement of the sale of 13 products for 19.1 million euros |
Date |
PDF
| Regulatory Event |
Content |
11/11/2008 |
|
Announcement of a co-marketing agreement with Pfizer to commercialise a new medicine that reduces cardiovascular risk in hypertense patients. |
|
4/11/2008 |
|
Announcement of a co-marketing agreement with MSD to commercialise in Spain a new medicine for type 2 diabetes. |
|
15/10/2008 |
|
Announcement of the plans to progress with the development of aclidinium bromide, jointly with the US partner Forest Laboratories, Inc., and reiterates 2008 financial guidance and gives a preview on 2009. |
|
23/09/2008 |
|
Announcement of receipt of 15 million dollars (€10,5 million) from Forest Laboratories in connection with Phase III development of aclidinium bromide. |
|
23/09/2008 |
|
Announcement of receipt of 15 million dollars (€10,5 million) from Forest Laboratories in connection with Phase III development of aclidinium bromide. |
|
03/09/2008 |
|
Correction to previous regulatory event. |
|
03/09/2008 |
|
Announcement of Phase III Topline results of aclidinium bromide. |
|
02/09/2008 |
|
Information related to the news appeared today. |
|
28/08/2008 |
|
1st Half 2008 Financial results presentation |
|
07/08/2008 |
|
Announcement of US$ 7,5 Mill Milestone income related to the development of AB + ICS. |
|
31/07/2008 |
|
Announcement of an initial agreement for the sale of one of its pharmaceutical plants |
|
20/05/2008 |
|
1st Quarter 2008 Financial results information. |
|
09/05/2008 |
|
Announcement of dividend approval and other agreements reached at today’s AGM. |
|
10/04/2008 |
|
Announcement of a € 17 mill. Milestone income related to the almotriptan commercialisation agreement in USA and Canada. |
|
03/04/2008 |
|
Announcement of next AGM on May 9th 2008 in Barcelona. |
|
03/04/2008 |
|
2007 Annual Corporate Governance Report |
|
29/02/2008 |
|
2nd Half 2007 Financial results information. |
|
28/01/2008 |
|
Sindicated loan of €275 Mill. with diverse banks has been communicated |
Date |
PDF
| Regulatory Event |
Content |
19/12/2007 |
|
Information related to the agreements reached at today’s Extraordinary AGM. |
|
19/12/2007 |
|
Closing of the acquisition of a portfolio of 8 products from Shire plc., as previously announced on October 8th. |
|
14/11/2007 |
|
3rd Quarter 2007 Financial results information. |
|
13/11/2007 |
|
Announcement of an Extraordinary AGM on December 19th in Barcelona. |
|
08/10/2007 |
|
Announcement of an agreement to acquire a portfolio of 8 products from Shire plc. |
|
03/09/2007 |
|
Closing of the acquisition of Hermal to Reckitt Benckiser PLC, after the German Authorities approval. |
|
24/07/2007 |
|
1st Half 2007 Financial Results information |
|
16/07/2007 |
|
Announcement of an agreement to acquire Hermal, the European prescription dermatology business of Reckitt Benckiser for £ 255 million |
|
10/07/2007 |
|
Additional information to the Prospectus of Initial Public Offering and Subscription Offering for shares of the Company. |
|
27/06/2007 |
|
Shareholders agreements. |
|
19/06/2007 |
|
Additional information to the Prospectus of Initial Public Offering and Subscription Offering for shares of the Company. |
|
12/06/2007 |
|
Additional information to the Prospectus of Initial Public Offering and Subscription Offering for shares of the Company |
